Systemic sclerosis & Raynaud's
The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the European Scleroderma Trials and Research (EUSTAR) cohort
Authors' conclusion
Results from the EUSTAR registry showed that HCQ was used by 2.6% of SSc patients. HCQ use did not improve the HAQ-DI, or CHFS when comparing HCQ users to non-HCQ users.
Study context
- Population
- Systemic Sclerosis (SSc) patients from the EUSTAR databaseSSc patients evaluated
- Participants
- 17,805 patients
- Exposure
- Hydroxychloroquine (HCQ) for at least 6 months vs matched SSc patients not using HCQ
- HCQn = 468
- Outcome
- Change in HAQ-DI and CHFS
- Follow-up
- Up to 365 days
Methodological detailspropensity-score matched (3:1 control: HCQ), EUSTAR registry
- Propensity-score matched (3:1 control: HCQ)
- EUSTAR registry
Main finding
As reported in the abstract
Change in HAQ-DI or CHFS
- No significant differences between the two groups in the change of Health Assessment Questionnaire disability index (HAQ-DI) or Cochin Hand Function Status (CHFS)
- all P > 0.05
Observational data: associations, not effects.
Further findings
- HCQ use among SSc patients
- 2.6% · 468
Original publication
The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort. Arthritis Res Ther. Published 27 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →